The Beatrice Hunter Cancer Research Institute logo
  • Dr. Sandra Turcotte, PhD


Associate Professor


Department of Chemistry and Biochemistry, Université de Moncton
Researcher in residence at Atlantic Cancer Research Institute
Research Chair, Canadian Cancer Society, NB

Research Interests:

Exploiting synthetic lethality in kidney cancer for the development of anticancer therapy; miRNA profiling and target prediction in Renal Cell Carcinoma; Characterization of the role of VHL in autophagy

Fighting kidney cancer the von Hippel-Lindau way

Dr Sandra Turcotte is Assistant Professor at the Université de Moncton and researcher in residence at the Atlantic Cancer Research Institute. She completed her PhD in Biochemistry at the Université du Québec à Montréal and Post-doctoral Fellowships at Stanford University in California and at the CRCHUM in Montreal. 
Her research focus on developing new targeted therapy for kidney cancer. Her studies identify a small molecule that kills renal cancer cells and spare normal cells. Her laboratory uses a variety of methods in cell and molecular biology to study the role of autophagy in kidney cancer. Dr Turcotte hold a Canadian Cancer Society Research Chair in New Brunswick and is a KRESCENT New Investigator awardee.

Involvement with BHCRI to date:

Dr. Turcotte is a BHCRI Senior Scientist




Rémi Rossignol building, Université de Moncton, 18 Antonine-Maillet avenue, Moncton, New Brunswick, Canada, E1A 3E9


Cuperlovic-Culf M, Cormier K, Touaibia M, Reyjal J, Robichaud S, Belbraouet M and Turcotte S. (2015). 1H NMR Metabolomics analysis of renal cell carcinoma cells: Effect of VHL inactivation on metabolism. Accepted in Int J of Cancer.

Cormier K, Curry RD, Betsch MP, Goguen JA, Vogels CH, Decken A, Turcotte S and Westcott SA. (2015). Synthesis, characterization, andanticancer activities of pyrogallol-based arylspiroborates. Journal of Heterocyclic chemistry, Epub print.

Jean S, Cormier K, Patterson AE, Vogels CM, Decken A, Robichaud G, Turcotte S and Westcott
SA. (2015) Synthesis, characterization and anticancer properties of organometallic Schiff base platinum
complexes. Canadian Journal of Chemistry, Epub print 21 May.

Reyjal J , Cormier K , Turcotte S. (2014). Autophagy and cell death to target cancer cells: exploiting
synthetic lethality as cancer therapies.Advances in experimental medicine and biology. 772: 167-188.

Reaume N, Graham GE, Tomiak E, Kamel-Reid S, Jewett MA, Bjarnason G, Blais N, Care M, Drachenberg D, Gedye C, Grant R, Heng D, Kollmannsberger C, Lattouf JB, Pause A, Reuther D, Soulieres D, Tanguay S, Turcotte S, Violette P, Wood L, Basiuk J and Pautler SE for the Kidney Cancer Research Network of Canada. (2013) Canadian Guideline On Genetic Screening for Hereditary Renal Cell Cancers, CUAJ (Canadian urology association journal),7 (9-10), 319-324

Chan DA, Sutphin PD, Nguyen P, Turcotte S, Lai EW, Banh A, Reynolds GE, Chi JT, Wu J, Solow-Cordero DE, Bonnet M, Flanagan JU, Bouley DM, Graves EE, Denny WA, Hay MP, Giaccia AJ. (2011). Targeting GLUT1 and the Warburg. Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality. Science Translational Medicine. 3(94): ra70-80.

Turcotte S and Giaccia AJ. (2010) Targeting cancer cells through autophagy for anticancer therapy. Curr Opin in Cell Biol. 22(2): 246-251

Hay MP, Turcotte S, Flanagan JU, Bonnet M, Chan DA, Sutphin PD, Nguyen P, Giaccia AJ and Denny WA. (2010) 4-Pyridylanilinothiazoles that selectively target von Hippel-Lindau deficient renal cell carcinoma cells by inducing autophagic cell death. J. Med. Chem. 53(2), 787-797.

Turcotte S, Sutphin PD and Giaccia AJ. (2008) Targeted therapy for the loss of von Hippel-Lindau in Renal Cell Carcinoma: A novel molecule that induces autophagic cell death. Autophagy 4(7).

Turcotte S, Chan DA, Sutphin PD, Hay MP, Denny WA and Giaccia AJ. (2008) A molecule targeting VHL-deficient Renal Cell Carcinoma that induces autophagy. Cancer Cell 14(1):90-102.

Site by: Spectacle Group